Japan Genomic Medicine Market Size & Forecast 2035
The Japan genomic medicine market was valued at USD 1.97 billion in 2025 and is projected to reach USD 6.46 billion by 2035, expanding at a 12.6% CAGR during 2026–2035.
Genomic medicine uses information from DNA, RNA and related molecular systems to support diagnosis, treatment selection, risk assessment, disease monitoring and drug development. The market covers sequencing and molecular-analysis instruments, reagents, clinical genomic tests, bioinformatics, genomic-data services and selected gene-editing research tools used in human medicine. It excludes therapeutic drug revenue, general laboratory testing without a genomic component, consumer wellness testing and agricultural genomics.
Japan is moving from project-based genomic research toward a national delivery system. The establishment of the Japan Agency for Medical Genomics, or GeMJ, created an implementation body for whole-genome programs, patient return of results and data infrastructure. At the same time, reimbursed cancer genomic profiling is expanding through new panels, companion-diagnostic claims and a growing hospital network.
Key Highlights
- Kits and reagents led with 52.4% of 2025 revenue, equal to USD 1.03 billion.
- Next-generation sequencing represented 37.6%, or USD 0.74 billion, making it the largest technology segment.
- Oncology accounted for 43.8%, equal to USD 0.86 billion, supported by reimbursed cancer genomic profiling and companion diagnostics.
- Hospitals and clinics generated 38.6%, or USD 0.76 billion, while research institutions accounted for USD 0.63 billion.
- Kanto held 44.2% of national revenue, equal to USD 0.87 billion; Kansai followed with USD 0.41 billion.
- Japan’s cancer genomic medicine network included 13 core hospitals, 32 designated hospitals and 263 affiliated hospitals from November 2026.
- The domestic commercial model is shifting from imported centralized profiling toward a mixed system of locally performed panels, domestic analysis and nationally governed genomic data.
Market Dynamics
GeMJ turns whole-genome analysis into an operating infrastructure
Japan’s Ministry of Health, Labour and Welfare established GeMJ within the National Cancer Center in March 2026. The organization is responsible for supporting the return of whole-genome findings to patients, promoting personalized medicine and building infrastructure for controlled data use in research and drug discovery.
The June 2026 whole-genome committee review showed operational scale: cancer-program whole-genome submissions had reached 11,982 cases and RNA sequencing covered 11,275 cases. The reported actionable-alteration rate was 57.9%, while treatment options were identified for 26.2%. In rare disease, 19,610 cases had been analysed through fiscal 2025, with 4,000 additional cases targeted in fiscal 2026.
These numbers create demand for sample logistics, high-throughput sequencing, quality control, variant interpretation and secure computing. The main constraint is no longer sequencing alone; it is converting results into timely clinical action.
Reimbursement is broadening the cancer-genomic market
Japan introduced insurance coverage for selected cancer gene-panel testing in 2019. The market is now widening through additional reimbursed panels. Illumina’s TruSight Oncology Comprehensive workflow became covered in June 2026 through a partnership involving Sysmex and RIKEN Genesis. In November, the Fujinokuni HOPE Oncopanel gained coverage with 410 cancer-related genes and 22 drug-metabolism genes.
The HOPE panel is reimbursed at 44,000 points for comprehensive genomic profiling, with a separate 12,000-point evaluation fee. This formal separation between laboratory analysis and clinical interpretation shows that expert review is an economic component of genomic medicine, not an unpaid administrative step.
The hospital network is expanding access but concentrating expertise
As of November 2026, Japan’s cancer-genomic network included 13 core hospitals, 32 designated hospitals and 263 affiliated hospitals. The number of affiliated hospitals increased from 259 in September to 263 in November.
Network expansion increases sample volume and geographic access, but interpretation remains concentrated in expert panels and designated centres. Vendors must therefore support both local sample collection and centralized analysis. Products that fit national data standards and expert-panel reporting workflows have an advantage over stand-alone instruments.
Distributed NGS is competing with referral testing
Japanese institutions can use central reference services or build internal sequencing capacity. Illumina’s distributable TSO Comprehensive workflow analyses more than 500 genes and supports local sample-to-report processing. Takara Bio’s Osaka University agreement establishes a clinical sequencing laboratory inside the university hospital and a joint research unit for genomic-medicine technology.
Internal testing can reduce transport and turnaround, but it requires adequate volume, technical staff, quality management and bioinformatics. Referral testing remains attractive for lower-volume hospitals. Japan is likely to retain a hybrid structure rather than move entirely to one model.
Japanese genomic data are gaining strategic value
The Fujinokuni HOPE panel was developed from data on 5,143 Japanese cancer cases. This addresses a persistent limitation in genomic medicine: reference datasets and variant interpretation can underrepresent Japanese and other Asian populations.
Domestic datasets can improve variant classification, trial matching and pharmacogenomic interpretation. Their value also creates governance responsibilities around consent, privacy, secondary research and cross-institution access. GeMJ’s data infrastructure will influence how commercial and academic users can work with nationally generated genomic information.
AI is entering analysis and laboratory operations
Takara Bio and Epistora signed an October 2026 agreement to explore AI-driven data analysis, bioinformatics, omics services, experimental design and manufacturing optimization. AI can reduce manual review and connect genomic, clinical and process data, but its outputs require traceability and human oversight.
Japan’s strongest opportunity lies in controlled clinical and research workflows rather than unvalidated automated interpretation. Systems that document model versions, input quality and review decisions will be easier to integrate into regulated environments.
Cost and workforce capacity remain material constraints
Sequencing cost has declined, but total genomic-medicine cost includes extraction, library preparation, analysis, storage, expert review, counselling and follow-up. Clinical geneticists, bioinformaticians and trained laboratory professionals remain limited relative to the expected volume.
Automation can lower manual workload, yet it does not remove the need for interpretation and governance. Capacity-building and standardized reporting are required to prevent the installed technology from becoming underutilized.
Market Segmentation
By product type
Kits and reagents accounted for 52.4% of 2025 revenue, equal to USD 1.03 billion. Library-preparation kits, sequencing chemistry, PCR reagents, extraction products, controls and clinical assay panels generate recurring revenue after instruments are installed. Expansion of reimbursed cancer panels directly increases this consumable opportunity.
Instruments and equipment represented 24.8%, or USD 0.49 billion. The segment includes short- and long-read sequencers, PCR systems, microarray scanners, automated extraction equipment and laboratory robotics. Instrument sales depend on research budgets, test volume and the economics of local versus centralized analysis.
By technology
Next-generation sequencing led with 37.6%, equal to USD 0.74 billion in 2025. Targeted panels, whole-exome sequencing, whole-genome sequencing, RNA sequencing and companion-diagnostic applications support the segment. Reimbursement and national programs are moving NGS beyond research institutions.
PCR and digital PCR represented 24.7%, or USD 0.49 billion. PCR remains central to focused mutation testing, validation and companion diagnostics. RIKEN Genesis’ AmoyDx lung-cancer panel illustrates how multiplex PCR can deliver several actionable biomarkers without the cost and complexity of broad NGS.
Bioinformatics accounted for 13.8%, equal to USD 0.27 billion. Variant calling, annotation, clinical interpretation, data integration and storage are becoming bottlenecks as whole-genome volume rises. AI-supported analysis will expand this segment, but clinical outputs require validation and auditability.
Microarrays held 8.4%, or USD 0.17 billion. Arrays remain relevant for genotyping, copy-number analysis and population-scale research, although sequencing is replacing them in several discovery applications.
Gene-editing tools represented 7.9%, equal to USD 0.16 billion. This segment covers research and translational tools used to model disease and develop genomic therapies; therapeutic product revenue is excluded.
By application
Oncology led with 43.8%, equal to USD 0.86 billion in 2025. Cancer genomic profiling, companion diagnostics, hereditary-cancer assessment and research sequencing support this share. Japan performs around 20,000 comprehensive genomic profiling tests annually, while the hospital network and reimbursed test menu continue to expand.
Paediatrics and rare genetic disorders represented 19.6%, or USD 0.39 billion. Whole-exome and whole-genome analysis can shorten prolonged diagnostic pathways for rare disease. National case volumes provide a foundation for clinical interpretation and research.
Cardiology held 9.4%, equal to USD 0.19 billion. Inherited cardiomyopathy, arrhythmia and lipid-disorder testing support demand, though uptake is less standardized than in oncology.
Infectious diseases accounted for 9.1%, or USD 0.18 billion. Pathogen sequencing, resistance analysis and outbreak research are included where genomic methods are used clinically or in public-health laboratories.
Endocrinology represented 6.7%, equal to USD 0.13 billion. Monogenic diabetes, endocrine tumour syndromes and pharmacogenomic applications support the segment.
By end user
Hospitals and clinics held 38.6% of 2025 revenue, equal to USD 0.76 billion. Reimbursed cancer profiling and clinical sequencing are shifting genomic expenditure toward healthcare delivery. Core and designated hospitals influence platform selection, reporting standards and expert-panel workflows.
Research institutions represented 31.8%, or USD 0.63 billion. RIKEN, national centres and other institutes remain major users of whole-genome, single-cell and multi-omics tools.
Academic institutions accounted for 18.9%, equal to USD 0.37 billion. Universities combine discovery research, hospital testing, translational development and workforce training.
Competitive landscape
Japan’s market combines domestic clinical-laboratory groups, biotechnology suppliers, pharmaceutical companies and international sequencing platforms. Sysmex and RIKEN Genesis connect clinical diagnostics, PCR panels and cancer genomic profiling. Chugai commercializes Foundation Medicine tests and integrates them with personalized-healthcare strategy. Takara Bio supplies research reagents, sequencing services and clinical-sequencing capabilities. Illumina provides sequencing platforms and a reimbursed distributed CGP assay.
Other relevant companies include QIAGEN, Thermo Fisher Scientific, Agilent Technologies, Oxford Nanopore Technologies, Eurofins, BML, SRL/H.U. Group, FALCO Biosystems, Mitsubishi Space Software, GeneticLab, Genesis Healthcare, LSI Medience and domestic bioinformatics providers.
Company Profiles
Sysmex and RIKEN Genesis
RIKEN Genesis is a Sysmex subsidiary focused on genomic diagnostics and personalized medicine. The group participated in the development and clinical implementation of the OncoGuide NCC Oncopanel, Japan’s first approved cancer gene-panel system, which gained insurance coverage in 2019.
In June 2026, RIKEN Genesis began contract testing with Illumina’s TSO Comprehensive after insurance coverage, providing a panel that analyses more than 500 genes. In August, it expanded the AmoyDx lung-cancer multiplex PCR panel to include HER2 mutations, bringing the panel to eight genes after the relevant approval and coverage steps. The portfolio allows the company to address both broad genomic profiling and faster focused companion diagnostics.
Chugai Pharmaceutical
Chugai commercializes FoundationOne CDx and FoundationOne Liquid CDx in Japan through its Roche relationship. The tissue assay analyses 324 genes together with genomic signatures including microsatellite instability and tumour mutational burden.
Chugai reported retaining the leading share of Japan’s comprehensive genomic profiling market in 2025. Its personalized-healthcare roadmap calls for continued CGP expansion, use of genomic solutions in pharmaceutical R&D and development of proprietary diagnostic support. In September 2026, FoundationOne CDx gained additional companion-diagnostic claims involving BRAF-altered glioma and ALK-positive solid tumours.
Takara Bio
Takara Bio supplies life-science reagents, genomic-analysis services and technologies for gene and cell therapy. The company opened Japan’s first private large-scale genome-analysis facility in 2000 and provides whole-genome sequencing and other contract services.
Its Osaka University agreement supports an in-hospital clinical sequencing laboratory and joint genomic-medicine research. In October 2026, Takara Bio signed an AI collaboration agreement with Epistora covering genomic analysis, bioinformatics, omics, research design and process optimization. Takara Bio became a wholly owned subsidiary of Takara Holdings in June 2026, while undertaking structural changes in response to research-budget pressure and price competition in genomic analysis.
Illumina Japan
Illumina supplies sequencing platforms, arrays, reagents and regulated oncology assays. TruSight Oncology Comprehensive became Japan’s first Illumina CGP test with national insurance coverage in June 2026 and its first reimbursed CGP deployment in Asia.
The test analyses DNA and RNA across more than 500 genes and uses a standardized sample-to-report workflow. The partnership with Sysmex and RIKEN Genesis combines Illumina’s regulated assay with local clinical testing and market access. Its strategic opportunity is expansion from research sequencing into reimbursed clinical workflows; the main requirement is continued local evidence, quality control and payer-aligned use.
Recent Developments:
- November 1, 2026 - Shizuoka Cancer Center and H.U. Group: The Fujinokuni HOPE Oncopanel gained national insurance coverage. The panel covers 410 cancer-related genes and 22 drug-metabolism genes and is based on 5,143 Japanese cancer cases.
- November 2026 - MHLW and C-CAT: Japan’s cancer genomic medicine network expanded to 263 affiliated hospitals, in addition to 13 core and 32 designated hospitals.
- October 14, 2026 - National Cancer Center, Kyoto University and Nagoya University: Researchers reported a method for analysing centromere variation using short-read whole-genome data from 3,332 people.
- October 1, 2026 - Takara Bio and Epistora: The companies agreed to explore AI-enabled genomic analysis, bioinformatics, multi-omics services and data-driven research workflows.
- September 16–18, 2026 - Chugai Pharmaceutical: FoundationOne CDx added companion-diagnostic capabilities for BRAF-altered glioma and ALK fusion-positive solid tumours.
- June 29, 2026 - MHLW whole-genome committee: Japan reported 11,982 cancer whole-genome submissions, 11,275 RNA-sequenced cases and 19,610 rare-disease cases analysed through fiscal 2025.
- June 1, 2026 - Illumina, Sysmex and RIKEN Genesis: TruSight Oncology Comprehensive obtained insurance coverage and entered contract testing in Japan, marking Illumina’s first reimbursed CGP deployment in Asia.
Strategic Key Takeaways
- Japan’s genomic medicine market adds USD 4.49 billion by 2035, with recurring reagents, interpretation and data services generating more durable revenue than instruments alone.
- Oncology’s USD 0.86 billion position reflects a functioning reimbursement and hospital network that other clinical applications have not yet matched.
- NGS holds USD 0.74 billion, but PCR retains a strong role in focused, faster and lower-cost companion diagnostics.
- Kanto controls USD 0.87 billion, yet new clinical laboratories and regionally developed panels are creating measurable opportunities in Kansai and Chubu.
- GeMJ converts national whole-genome activity into an institutional market for sequencing, data infrastructure, interpretation and patient return of results.
- Japan-developed reference data can improve interpretation for Japanese patients and reduce dependence on datasets dominated by other populations.
- Insurance coverage is the critical commercialization threshold; regulatory approval without reimbursement does not guarantee routine hospital adoption.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Japan Genomic Medicine Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
